Benjamin D. Dickson
University Of Auckland Symonds St Auckland 1010 New Zealand
Auckland, AUK 1010, New Zealand
Auckland, AUK 1010, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.
Journal: Journal of medicinal chemistry
Published: July 15, 2024
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.
Journal: RSC medicinal chemistry
Published: March 13, 2023
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 27, 2021
Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer.
Journal: Cancers
Published: November 26, 2020
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Journal: International journal of radiation biology
Published: September 07, 2019
Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
Journal: Biochemical pharmacology
Published: August 05, 2019
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors.
Journal: Molecules (Basel, Switzerland)
Published: March 04, 2019
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Journal: Biochemical pharmacology
Published: May 29, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026